These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 20338711

  • 1. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, Bille J, Chang SC, da Luz Martins M, Duse A, Dzierzanowska D, Ellis D, Finquelievich J, Gould I, Gur D, Hoosen A, Lee K, Mallatova N, Mallie M, Peng NG, Petrikos G, Santiago A, Trupl J, VanDen Abeele AM, Wadula J, Zaidi M, Global Antifungal Surveillance Group.
    Diagn Microbiol Infect Dis; 2010 Jun; 67(2):162-71. PubMed ID: 20338711
    [Abstract] [Full Text] [Related]

  • 2. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
    Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, Newell VA.
    J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
    [Abstract] [Full Text] [Related]

  • 3. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ng KP, Colombo A, Finquelievich J, Barnes R, Wadula J, Global Antifungal Surveillance Group.
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [Abstract] [Full Text] [Related]

  • 4. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E, Global Antifungal Surveillance Study.
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [Abstract] [Full Text] [Related]

  • 5. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G, Sánchez-Vargas LO, Villar-Vidal M, Eraso E, Alkorta M, Hernández-Almaraz JL.
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [Abstract] [Full Text] [Related]

  • 6. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, McCarthy DI, Rinaldi MG, Redding SW.
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [Abstract] [Full Text] [Related]

  • 7. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
    Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ, ARTEMIS DISK Global Antifungal Surveillance Group.
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
    [Abstract] [Full Text] [Related]

  • 8. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S.
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL, Cheng HH, Lo HJ.
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [Abstract] [Full Text] [Related]

  • 10. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA, Global Antifungal Surveillance Group.
    J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
    [Abstract] [Full Text] [Related]

  • 11. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
    Hüseyin A, Sancak B, Arikan S.
    Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
    [Abstract] [Full Text] [Related]

  • 12. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
    Lee SC, Lo HJ, Fung CP, Lee N, See LC.
    J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
    [Abstract] [Full Text] [Related]

  • 13. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
    Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, Gibbs DL, Newell VA.
    J Clin Microbiol; 2006 Oct; 44(10):3551-6. PubMed ID: 17021081
    [Abstract] [Full Text] [Related]

  • 14. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
    Buchta V, Vejsova M, Vale-Silva LA.
    Folia Microbiol (Praha); 2008 Oct; 53(2):153-60. PubMed ID: 18837162
    [Abstract] [Full Text] [Related]

  • 15. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA.
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [Abstract] [Full Text] [Related]

  • 16. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.
    Kronvall G, Karlsson I.
    J Clin Microbiol; 2001 Apr; 39(4):1422-8. PubMed ID: 11283066
    [Abstract] [Full Text] [Related]

  • 17. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
    Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ.
    J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
    [Abstract] [Full Text] [Related]

  • 18. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
    Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ.
    J Clin Microbiol; 2004 Jul; 42(7):3142-6. PubMed ID: 15243073
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M, Scaltrito MM, Morace G, GISIA-2 Group.
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [Abstract] [Full Text] [Related]

  • 20. Use of the BIOMIC Video System to evaluate the susceptibility of clinical yeast isolates to fluconazole and voriconazole by a disk diffusion method.
    Dóczi I, Mestyán G, Puskás E, Nikolova R, Barcs I, Nagy E.
    Acta Microbiol Immunol Hung; 2006 Jun; 53(2):135-44. PubMed ID: 16956125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.